AMLo Biosciences

Dr Marie Labus, our CEO spoke at the UK Parliamentary Science, Innovation and Technology Committee Innovation Showcase on 17 December 2024, where she explained our groundbreaking work in #melanoma #diagnostics and how this has resulted in our biomarker prognostic test #AMBLor®. She also highlighted the challenges facing small diagnostic companies in bringing innovative products into the UK healthcare market. Find out more and watch the full session: https://bit.ly/3CVwrMv AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor® test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. AMBLor® has received its UKCA mark in the UK. #dermatology #dermatopathology #histopathology #oncology #cancerresearch #biomarkers #HealthcareInnovation

AMLo Biosciences are pleased to share the Melanoma Focus Patient Conference 2025 taking place 27-28 February in Birmingham, UK. This is a valuable event for all #melanoma patients and family members to learn about current research into melanoma and living well with melanoma, as well as the opportunity to ask your questions. #mpc2025

Using data from US cancer registries and national health statistics, new cases of cutaneous #melanoma for 2025 are estimated at 104,960 with 8,430 predicted melanoma deaths. https://bit.ly/4gxZOSL Unsurprisingly, the sunshine states California (11,140) and Florida (10,290) top the new case leader board by state and Alaska (90) was predictably at the bottom. The 5-year relative survival rate provides some reassurance for melanoma patients, appearing in the top four contemporary survival for cancer statistics, at 94%. The authors explain that this is largely due to new regimens of immunotherapy and targeted therapy, particularly for metastatic melanoma, and note that 5-year relative survival for distal stage melanoma has doubled to 35% in 2014-2020. AMLo Biosciences offer physicians a biomarker prognostic test, #AMBLor®, that identifies which early-stage melanomas are at low risk of progression. This additional prognostic information at diagnosis, can assist with personalised management decisions and offer patients reassurance around the risk of their cancer returning. AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor® test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. AMBLor® has received its UKCA mark in the UK. #dermatology #dermatopathology #histopathology #oncology #cancerresearch #biomarkers #HealthcareInnovation

Today, we proudly celebrate the International Day of Women and Girls in Science by acknowledging our incredible team at AMLo Biosciences. As a female-founded and female-led company, we are dedicated to fostering an environment where women excel and thrive. With a 70% female workforce, our team is at the forefront of driving innovative research into #melanoma prognostics and developing products that benefit patients and clinicians. We encourage future generations of women and girls to continue to contribute to the world of science. #WomenInScience #WomenInSTEM #GirlsInScience #Innovation #CancerResearch #skincancer

Epidemiological evidence implies that there is currently a high level of overdiagnosis of #melanoma. This not due to diagnostic error, as these lesions meet current diagnostic criteria to be labelled cancerous, although they would not cause death. https://bit.ly/4grdQ8X There has been recent evidence presented that some Spitz tumours may be indistinguishable from usual melanomas (without sophisticated genomic testing) and these might form a significant subset of the “pseudomelanomas”. There exists a clear need for improved testing that can help pathologists accurately differentiate between malignant and benign tumours. The authors add that such testing could reduce the need for surgery and other interventions into melanoma lesions and reduce anxiety in the patient population. #AMBLor®, our prognostic test (that reliably identifies early-stage melanomas at low risk of progression regardless of Breslow depth) is one option available to aid diagnosis. In our IUK funded study CATNAP, we investigated the utility for AMBLor® to help classify a range of pigmented lesions as benign or malignant which generated some interesting findings. We are currently validating these early results in larger cohorts of patient samples with the hope of extending utility of AMBLor® beyond early-stage melanoma. https://bit.ly/4hvbuaw AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor® test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. AMBLor® has received its UKCA mark in the UK. #dermatology #dermatopathology #histopathology #oncology #cancerresearch #biomarkers #HealthcareInnovation

AMLo Biosciences really like this campaign for Skin Cancer UK. Using a paper copy of the Sunbeds Regulation Act 2010 it graphically demonstrates the damage that sunbed use has on our skin. This really resonated with us and we urge people to avoid using sunbeds. #Melanoma is the deadliest #skincancer. It's very treatable if caught early but your risk can be lowered by protecting your skin from UV damage delivered by the sun or sunbed use.

Cancer is more than a medical diagnosis—it’s a deeply personal experience. People-centred care means seeing the whole person and meeting their unique needs with compassion and empathy. #WorldCancerDay #UnitedByUnique #worldcancerday #Melanoma is the most aggressive form of skin cancer and the stress of receiving a diagnosis can severely affect patients. Work, relationships and many other aspects of daily life can be affected by the stress of diagnostic procedures, anxiety at every scan and constant worry about the cancer returning. AMLo Biosciences believe that providing detailed prognostic information at diagnosis can significantly ease patient anxiety. #AMBLor®, our innovative prognostic test, can be integrated with initial pathology tests to identify early-stage melanomas at low risk of progression. This reduces the need for further invasive procedures and minimises the frequency of follow-up appointments. We firmly advocate for personalised care, recognising that each individual's melanoma journey is unique. AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor® test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. AMBLor® has received its UKCA mark in the UK. #dermatology #dermatopathology #histopathology #oncology #cancerresearch #biomarkers #HealthcareInnovation

A recently published Australian article debates the complexities of a national #melanoma screening programme and concludes understanding an individual’s risk and targeting high-risk people gives better results than screening everyone. The authors explain that screening everyone is likely to lead to over diagnosis of low risk, slow-growing cancers (in-situ) that might never cause harm. Receiving any cancer diagnosis causes stress and can result in unnecessary surgeries, and costs. Screening high-risk groups to find disease early is the proposed approach to improve survival rates and ensure best use of resources. Risk factors  include fair skin, red hair, a history of sunburns, many moles and/or a family history. They also advise that new technologies could improve the accuracy of melanoma diagnosis and risk assessment. https://bit.ly/4fJIzxx. Our prognostic test #AMBLor® enables risk stratification of individuals with early-stage melanomas. AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor® test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. AMBLor® has received its UKCA mark in the UK.   #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers #HealthcareInnovation #SkinCancerAwareness

AMLo Biosciences want to share this post to help raise further awareness of the heightened risk of melanoma that firefighters face. Due to their exposure to carcinogenic chemicals as well as exposure to long periods of sun exposure while working outdoors, this put them at greater risk of #skincancer.

AMLo Biosciences is pleased to report the successful completion of our Innovate UK and Northstar Group, investor partnership award (CATNAP) CATNAP was a large cohort study focusing on the diagnostic utility of #AMBLor® for classification and risk determination of atypical, pigmented lesions in the ageing population, providing additional indications for AMBLor®, which is currently available as a prognostic test to segment early-stage melanomas that are at low risk of progression. As recent statistics have shown, the incidence of #skincancer is on the rise in the elderly population and this study aims to investigate how well AMBLor® performs when testing pigmented lesions, indeterminant melanocytic lesions, and Spitz tumours. We are thrilled to report the successful completion of our CATNAP study, on time and on budget. The results have exceeded our expectations, support two new indications for #AMBLor®. We look forward to sharing the detailed results of this study in due course. AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor® test meets  the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. AMBLor® has received its UKCA mark in the UK. amlo-biosciences.com #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers #HealthcareInnovation Chi Onwurah, British Skin Foundation British In Vitro Diagnostics Association (BIVDA), North East Times, Newcastle University, Esperante, Ascension